Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908070 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL2309917 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29370319 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL119451 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29401991 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL30096349 | 0.92 | CASP3 (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL29391787 | 0.91 | MDM4 (0.51) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL27142935 | 0.91 | KMT2A (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL27142932 | 0.91 | KMT2A (0.54) | MDM4TP53CASP3KMT2ASLC17A5 | |
| SCHEMBL20526769 | 0.90 | MDM4 (0.56) | MDM4TP53CASP3KMT2ASLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107865289-A | A kind of chitosan antiseptics for natural food and preparation method thereof | 成都新柯力化工科技有限公司 | 2018-04-03 | — | — | CN | claimed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240270809-A1 | ORAL GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-08-15 | — | — | US | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| US-11684652-B2 | HMGB1 antagonist treatment of acute lung injury | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230149505-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115666623-A | Oral GLP receptor agonists | 赫普泰雅治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2003014147-A1 | NOVEL DEPSIPEPTIDES AND PROCESS FOR PREPARING SAME | CUBIST PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-1999054321-A1 | SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
| EP-0883602-A2 | LIPIDS AND THEIR USE, FOR EXAMPLE, IN LIPOSOMES | Sourovoi, Andrej (DE) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997030024-A2 | LIPIDS AND THEIR USE, FOR EXAMPLE, IN LIPOSOMES | SOUROVOI ANDREJ (DE) | 1997-08-21 | — | — | WO | disclosed |
| EP-0281283-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-10 | — | — | EP | disclosed |
| EP-0204374-B1 | TRIPEPTIDIC COMPOUNDS HAVING HYPOTENSIVE ACTIVITY | POLIFARMA S.p.A. (IT) | 1992-12-30 | — | — | EP | disclosed |
| US-5051404-A | Tripeptides of pyroglutamic acid, proline, tryptophan, phenylalanine or tyrosine and a natural aminoacid | ENIRICERCHE, S.P.A. (IT) | 1991-09-24 | — | — | US | disclosed |
| US-4910212-A | Containing 1,2,4-triazole or imidazole ring | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-20 | — | — | US | disclosed |
| EP-0281283-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-07 | — | — | EP | disclosed |
| EP-0204374-A2 | Tripeptidic compounds having hypotensive activity | POLIFARMA S.p.A. (IT) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149505-A1 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | HMGB1, HMGB3, HMGB2 | MDM4 4157/4885TP53 2129/4885CASP3 159/4885 |
| US-11684652-B2 | HMGB1 antagonist treatment of acute lung injury | HMGB1, HMGB3, HMGB2 | MDM4 3344/4885TP53 1889/4885CASP3 165/4885 |
| US-20240270809-A1 | ORAL GLP RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | MDM4 4328/4885TP53 3779/4885CASP3 1192/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | MDM4 4385/4885TP53 4379/4885CASP3 3511/4885 |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | GLP1R, GIPR, NPY4R | MDM4 4499/4885TP53 4559/4885CASP3 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.